Clinical Trials Logo

18F-FDG clinical trials

View clinical trials related to 18F-FDG.

Filter by:
  • None
  • Page 1

NCT ID: NCT06190574 Completed - Neuroblastoma Clinical Trials

Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma

Start date: July 30, 2021
Phase:
Study type: Observational

the primary histologic origin of extracranial solid tumors in children is malignant embryonic cells, including Neuroblastoma (NB) , Hepatoblastoma(HB), and kidney, wilms' tumor(WT). Their main clinical symptoms are large abdominal masses, the most common lymph node metastasis . NB accounts for 15% of childhood cancer deaths, but some low-risk NB can disappear on its own. The International Neuroblastoma Risk Group Staging System (INRGSS) was used to determine Risk before NB treatment, whereas the INRGSS was entirely based on the Neuroblastoma diagnosis, illustrating the importance of imaging in the assessment of NB.18F-FDG is the most commonly used agent in PET imaging of tumor. It can reflect the glucose metabolism of tumor and is widely used in the diagnosis, staging, evaluation of curative effect and prognosis prediction of tumor In this study, the investigators retrospectively analyzed 18F-FDG PET/CT or PET/MRI images from patients with NB, HB, and WT. The investigators sought to assess whether these images provide useful information for diagnosis and prognosis.

NCT ID: NCT05884463 Completed - Diagnosis Clinical Trials

18F-FAPI PET Imaging in Pancreatic Adenocarcinoma

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

To explore the potential efficacy of 18F-FAPI-04 PET/CT for PDAC tumour staging and compare the results with those obtained using 18F-FDG PET/CT.

NCT ID: NCT04588064 Recruiting - Lung Adenocarcinoma Clinical Trials

18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

To evaluate the potential usefulness of 68Ga-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in lung adenocarcinoma, compared with 18F-FDG PET/CT.

NCT ID: NCT03741231 Completed - Melanoma Clinical Trials

18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy

IMMUNOPET
Start date: March 1, 2018
Phase:
Study type: Observational

Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung cancer treated by immunotherapy.